Hypertriglyceridemia refers to abnormalities in the concentration of triglycerides in the circulation and is a key modifiable risk factor for cardiovascular (CV) disease and, with very high levels…
DRG Epidemiology's coverage of NAFLD comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report prevalence of NAFLD for each country, as well as…
The chronic obstructive pulmonary disease (COPD) therapy market continues to suffer from the absence of any agents that can reverse disease progression and repair lung tissue. Smoking cessation is…
Idiopathic pulmonary fibrosis (IPF) is one of the most common interstitial lung diseases and is characterized by an irreversible loss of lung function. Roche’s pirfenidone (Esbriet) was the first…
KEY BENEFITS AND USES Pinpoint current drug positioning and uptake in one snapshot to facilitate forecasting. Drill down into physicians’ treatment sequences and understand which drugs to…
TNF-alpha inhibitors (e.g., Janssen’s Remicade, AbbVie’s Humira) are the mainstay of biological treatment for moderate to severe Crohn’s disease (CD), while newer biologics (i.e., Takeda’s…
The systemic sclerosis (SSc) pipeline is replete with therapies targeting pathways underlying autoimmunity, inflammation, and fibrosis, particularly in the early phases of development. Currently,…
Research on the human microbiome is expanding beyond C. difficile, with microbiome-based therapies reaching the clinical trial phase of development for additional disease areas. Investments in this…
The U.S. market for dry eye disease (DED) therapies witnessed notable developments in 2019, including Novartis’s acquisition of Xiidra and the launch of Sun Ophthalmics’ Cequa at a competitive…
DRG Epidemiology's coverage of dysthymia comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report the prevalence of dysthymia for each country, as…
DRG Epidemiology's coverage of dysthymia comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report the prevalence of dysthymia for each country, as…
DRG Epidemiology's coverage of dysthymia comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report the prevalence of dysthymia for each country, as…
DRG Epidemiology's coverage of dysthymia comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report the prevalence of dysthymia for each country, as…
DRG Epidemiology's coverage of dysthymia comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report the prevalence of dysthymia for each country, as…
DRG Epidemiology's coverage of dysthymia comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report the prevalence of dysthymia for each country, as…